Undersøgelsen var et ‘ åbent ’ forsøg, hvilket betyder, at både lægen og patienterne vidste, hvilken medicin patienterne tog, fordi Ferriprox tages gennem munden, hvorimod deferoxamin gives som en subkutan infusion (en meget langsom injektion under huden) i løbet af natten.
The study was an ‘ open label’ study, meaning that the doctor and patients knew which medicine they were using, because Ferriprox is given by mouth, whereas deferoxamine is given by subcutaneous infusion (a very slow injection under the skin) overnight.